Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/10474
Full metadata record
DC FieldValueLanguage
dc.contributor.authorÇakmak, E.en_US
dc.contributor.authorSarı, Hakan İsmailen_US
dc.contributor.authorCanoz, Ö.en_US
dc.contributor.authorEser, B.en_US
dc.contributor.authorAltuntaş, F.en_US
dc.contributor.authorÇetin, M.en_US
dc.contributor.authorÜnal, A.en_US
dc.date.accessioned2019-08-16T13:19:11Z-
dc.date.available2019-08-16T13:19:11Z-
dc.identifier.issn1300-199X-
dc.identifier.urihttps://hdl.handle.net/11499/10474-
dc.identifier.urihttps://doi.org/10.5152/etd.2015.150001-
dc.description.abstractObjective: P53, Bcl-2, and Fas proteins play significant roles in lymphoid cell apoptosis. These proteins affect the prognosis and treatment response of lymphoma and various malignancies. The aim of the present study was to investigate the effects of P53, Bcl-2, and Fas protein expression on treatment and prognosis in patients with primary gastrointestinal diffuse large B-cell lymphoma. Materials and Methods: Thirty-nine patients with primary gastrointestinal diffuse large B-cell lymphoma were included in the study. Immunohistochemical staining was performed to analyze P53, Bcl-2, and Fas protein expression levels in paraffin sections. Results: We examined 39 patients with primary gastrointestinal diffuse large B-cell lymphoma, 21 males and 18 females, with a median age of 54 years. P53 protein expression was detected in 24 patients (61.5%), Bcl-2 protein expression was detected in 26 (67%), and Fas protein expression was detected in 28 (72%). The five-year overall survival rate was significantly lower in patients with P53 and Bcl-2 expression; on the other hand, we did not find a significant difference in the five-year overall survival with respect to Fas protein expression. Conclusion: We found that P53 and Bcl-2 protein expression had a negative effect on prognosis and survival in patients with primary gastrointestinal diffuse large B-cell lymphoma. However, Fas protein expression had no effect on prognosis and survival. Taken together, patients with P53 and Bcl-2 expression should be considered to have a high risk from the beginning, and these patients should undergo aggressive treatments. © 2015 by Erciyes University School of Medicine.en_US
dc.language.isoenen_US
dc.publisherAVES Ibrahim Karaen_US
dc.relation.ispartofErciyes Tip Dergisien_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBcl-2en_US
dc.subjectFasen_US
dc.subjectLymphomaen_US
dc.subjectP53en_US
dc.subjectPrognosisen_US
dc.subjectbiological markeren_US
dc.subjectbleomycinen_US
dc.subjectcisplatinen_US
dc.subjectcyclophosphamideen_US
dc.subjectcytarabineen_US
dc.subjectdexamethasoneen_US
dc.subjectdoxorubicinen_US
dc.subjectetoposideen_US
dc.subjectFas antigenen_US
dc.subjectfolinic aciden_US
dc.subjectmethotrexateen_US
dc.subjectmethylprednisoloneen_US
dc.subjectprednisoloneen_US
dc.subjectprotein bcl 2en_US
dc.subjectprotein p53en_US
dc.subjectvincristineen_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectArticleen_US
dc.subjectcancer chemotherapyen_US
dc.subjectcancer prognosisen_US
dc.subjectclinical articleen_US
dc.subjectelectrocorticographyen_US
dc.subjectfemaleen_US
dc.subjectgastrointestinal diseaseen_US
dc.subjecthumanen_US
dc.subjectimmunohistochemistryen_US
dc.subjectInternational Prognostic Indexen_US
dc.subjectlactate dehydrogenase blood levelen_US
dc.subjectlarge cell lymphomaen_US
dc.subjectmaleen_US
dc.subjectmiddle ageden_US
dc.subjectoverall survivalen_US
dc.subjectprotein expressionen_US
dc.subjectretrospective studyen_US
dc.subjecttreatment responseen_US
dc.titlePrognostic significance of P53, Bcl-2, and fas expression in patients with primary gastrointestinal diffuse large B-cell lymphomaen_US
dc.typeArticleen_US
dc.identifier.volume37en_US
dc.identifier.issue3en_US
dc.identifier.startpage102en_US
dc.identifier.endpage105en_US
dc.identifier.doi10.5152/etd.2015.150001-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.scopus2-s2.0-84944735471-
dc.identifier.trdizinid230323en_US
dc.identifier.wosWOS:000364023200004en_US
dc.identifier.scopusqualityQ4-
dc.ownerPamukkale University-
item.fulltextWith Fulltext-
item.languageiso639-1en-
item.openairetypeArticle-
item.cerifentitytypePublications-
item.grantfulltextopen-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Files in This Item:
File SizeFormat 
document (1).pdf121.65 kBAdobe PDFView/Open
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

1
checked on Nov 16, 2024

Page view(s)

88
checked on Aug 24, 2024

Download(s)

20
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.